Ukraine drug imports declined by almost 30% in 2014

23 January 2015
ukraine-big

Drug imports to Ukraine in 2014 decreased by almost 30%, compared to 2013, according to the Ukrainian State Service on Drugs.

This is mainly due to the increase of prices caused by the devaluation of the Ukrainian currency – hryvnia.

The same position is endorsed by Vladimir Ignatov, executive director of the Association of International Pharmaceutical Manufacturers in Ukraine, who comments: “There are several reasons of the current situation in the Ukrainian pharmaceutical market. On the one hand, we lost the Crimea and we have a military conflict in the eastern part of the country. On the other hand, everyone understands that the value of both imported finished products and components for the production of drugs in Ukraine has increased due to devaluation of the local currency, which declined by more than 100%. Also the government introduced a value-added tax on drugs as well as drug imports, which also contributed to the increase of drug prices.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical